Proactive Investors
Published Apr 12, 2024 11:46
Updated Apr 12, 2024 12:15
US biopharma first quarter earnings seen stable amid low expectations
Proactive Investors - Expectations for US biopharma companies' first quarter earnings are low given the typical seasonality across the sector and new healthcare plan signups, analysts at the Bank of America (NYSE:BAC) believe.
“We don't expect many guidance changes; a stable earnings season should warrant continued generalist interest in biopharma,” the analysts wrote in a note.
They are bullish on Merck & Co Inc (NYSE:MRK, ETR:6MK) and Vertex Pharmaceuticals Inc (NASDAQ:VRTX, ETR:VX1) on their view the companies are up against beatable growth expectations.
However, they are more cautious on Bristol-Myers Squibb (NYSE:BMY) Co (NYSE:BMY, ETR:RM, OTC:BMYMP) given a typically tough Q1, with portfolio launch likely to inflect in the second half of the year or 2025.
Pharmaceutical highlights
Biopharma highlights
Read more on Proactive Investors CA
Disclaimer
Written By: Proactive Investors
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.